Daiichi's Handsome Buyout Price Validates Plexxikon's Business Model
By
Emily Hayes / Email the Author / IN VIVO March 2011, Vol. 29, No. 3
Around The Industry / Word Count: 1781 / Article # 2011800051
Executive Summary
In an era in which biotechs struggle to get financing and Big Pharma is hungry for new drugs but typically favors deals that delay rewards, Plexxikon Inc. appears to have been dealt a top R&D hand and played its cards exceedingly well. Its strategy has culminated in one of the priciest private buyouts in recent history, its $805 million up-front acquisition by Japan’s Daiichi Sankyo Co.
Ltd.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.